AngioVac Aspiration Therapy Registry

A Multicenter, International, Retrospective Observational Study Evaluating the Safety and Effectiveness of the AngioVac System Across Clinical Indications

As a structured, multinational retrospective registry the AVATAR Registry addresses the following scientific aspects through systematic data collection, centralized quality control, and robust statistical analysis in patients that were treated with the AngioVac Aspiration System:

1. Quantify Real-World Safety: Composite adverse event rates across diverse populations and indications

2. Assess Effectiveness: Technical and clinical success rates stratified by indication

3. Identify Predictors: Clinical, procedural, and anatomical factors predicting success versus complications

4. Generate Publishable Cohorts: Sufficient statistical power (approx. 1000 patients across 8 indication cohorts) for:

   • Indication-specific outcomes
   • Multivariable prediction models
   • Time-to-event analyses (30-day and 12-month mortality)

5. Establish Best Practices: Evidence-based recommendations for patient selection, procedural technique, and follow-up

Inclusion Criteria:

1. Age ≥18 years at time of AngioVac procedure
2. Patient underwent percutaneous AngioVac aspiration (any AngioVac model or version used clinically during study period)
3. Procedure performed within study period (January 2018 (or site's institutional start date) - June 2026)
4. Written informed consent OR documented waiver/exemption from ethics authority (per local regulations per GDPR)

Exclusion Criteria:

1. Insufficient documentation to assess primary safety or effectiveness endpoints (e.g. defined as >20% missing data in core endpoint variables)
2. Patient objection to retrospective data use (where required by local law; GDPR Article 21 opt-out; honored without study impact)
3. Non-AngioVac procedures: Patients undergoing thrombus/vegetation removal by surgery or other percutaneous devices only (not AngioVac)